← All trials
NCT04547660
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 16, 2020
- Primary completion
- Jul 31, 2021
- Completion date
- Oct 31, 2021
- First posted
- Sep 14, 2020
- Last posted
- Sep 14, 2020
- Enrollment
- 160
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Federal University of Health Science of Porto AlegreLead sponsor
- Federal University of Rio Grande do SulStudy director
- Federal University of Health Science of Porto AlegreOverall official - principal investigator
- Federal University of Rio Grande do SulCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.